

Curriculum Vitae

Name: Florian R. Schroeck, MD, MS

Position: Section Chief of Urology
White River Junction VA Medical Center, White River Junction, VT
Associate Professor of Surgery (Urology) and of The Dartmouth Institute
Dartmouth-Hitchcock Medical Center, Lebanon, NH

Address: 215 North Main Street
White River Junction, VT 05009
email: florian.r.schroeck@dartmouth.edu

Citizenship: United States and Germany

Education and Training

2011-2014	University of Michigan, Ann Arbor, MI	Fellow, Health Services Research
2011-2014	University of Michigan, Ann Arbor, MI	Fellow, Urologic Oncology
2011-2012	University of Michigan, Ann Arbor, MI	MS, Healthcare Research
2008-2011	Duke University, Durham, NC	Resident, Urology
2007-2008	Duke University, Durham, NC	Fellow, Urologic Oncology
2006-2007	Duke University, Durham, NC	Resident, Urology
2005-2006	Duke University, Durham, NC	Intern, General Surgery
2004-2005	Urologische Klinik München-Planegg, Munich, Germany	Intern, Urology
1997-2004	Technische Universität München, Munich, Germany	MD, Summa Cum Laude

Licensure and Certification

2016	American Board of Urology Certifying Examination (Board Certification)
2014	New Hampshire, Physician (#16609)
2014	New Hampshire, DEA license
2011	American Board of Urology Qualifying Examination
2010	Michigan, Medical Doctor (#4301097580), inactive

Academic Appointments

2019-present	Associate Professor of Surgery (Urology), Geisel School of Medicine at Dartmouth, Lebanon, NH
2019-present	Associate Professor of The Dartmouth Institute, Geisel School of Medicine at Dartmouth, Lebanon, NH
2014-2019	Assistant Professor of Surgery (Urology), Geisel School of Medicine at Dartmouth, Lebanon, NH
2014-2019	Assistant Professor of The Dartmouth Institute, Geisel School of Medicine at Dartmouth, Lebanon, NH
2011-2014	Clinical Lecturer, Department of Urology, University of Michigan, Ann Arbor, MI

Positions and Employment

2014-present	Investigator, Norris Cotton Cancer Center at Dartmouth, Cancer Population Science Research Program
2014-present	Staff Urologist, Dartmouth-Hitchcock Medical Center, Lebanon, NH
2014-present	Section Chief of Urology, White River Junction VA Medical Center
2014-present	Research Faculty, VA Outcomes Group, White River Junction, VT

Honors and Awards

- May 2018 Third prize at the national “Early Career Investigator Showcase” at the 113th American Urological Association Annual Meeting, representing the New England Section of the American Urological Association
- May 2018 Best Poster in the “Practice Patterns” session, Annual Meeting of the American Urological Association, for “A national study of risk-aligned surveillance practice for non-muscle invasive bladder cancer” at the 113th American Urological Association Annual Meeting
- May 2017 Best Poster in the session “General & Epidemiological Trends & Socioeconomics: Value of Care: Cost and Outcomes Measures II” for the abstract entitled “Development of a Natural Language Processing system to generate longitudinal pathology data” at the 112th American Urological Association Annual Meeting
- July 2015 Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 1 Career Development Award
- May 2015 Conquer Cancer Foundation / American Society of Clinical Oncology Career Development Award
- December '14 Dow Career Development Award in Surgery, Dept. of Surgery, Dartmouth-Hitchcock Medical Center
- May 2014 Outstanding Poster in Oncology for the abstract entitled “Do Prostate Cancer Patients Receiving the “Best Care” have Better Outcomes”, Annual Meeting of the American Urological Association, Orlando, Florida
- March 2014 First Prize in the Julian Wan Annual Research Award, Department of Urology, University of Michigan for “The Impact of Technology Diffusion on Treatment for Prostate Cancer”
- December '13 First Prize of the Young Urologic Oncologists for the abstract “The Impact of Technology on the Treatment of Prostate Cancer”, presented at the 14th Annual Meeting of the Society of Urologic Oncology
- October 2013 Recipient of the Traveling Fellowship Award of the North Central Section of the AUA for the manuscript entitled “Regional Variation in Prostate Cancer Quality of Care”
- October 2013 Best poster in the Outcomes / Socioeconomics poster session for the abstract entitled “Technology Diffusion and Diagnostic Testing For Prostate Cancer” at the 87th Annual Meeting of the North Central Section of the AUA
- May 2013 Oncology Trainee Travel Award for ASCO Annual Meeting, Conquer Cancer Foundation
- June 2011 First Place Winner Academic Achievement Award, Duke University Division of Urology
- June 2010 First Place Winner Academic Achievement Award, Duke University Division of Urology
- June 2009 Third Place Winner Academic Achievement Award, Duke University Division of Urology
- March 2009 First Place Winner of the Montague Boyd Essay Contest of the Southeastern section of the AUA for “Defining potency: A comparison of the IIEF-5 and the EPIC”
- May 2008 AUA Gerald P. Murphy Scholar
Distinction in the study of prostate cancer, AUA Annual Meeting, Orlando FL
- March 2008 Duke Comprehensive Cancer Center annual meeting outstanding poster presentation award for “Predictors for satisfaction and regret after three different types of radical prostatectomy.”
- August 2007 SBUR/AUA summer research conference (“Clinical Trials and Outcomes Research”) travel award

Professional Organizations

- 2017-present Urological Society for American Veterans (USAV)
- 2014-present New England Section of the American Urological Association
- 2011-present Society of Urologic Oncology
- 2005-present American Urological Association

Research Interests

Health Services Research, Quality in Cancer Care, Implementation Science, Technology Diffusion, Health Policy

Grant Support**CURRENT:**

- 2019 – 2023 VA HSR&D Merit Grant – IIR 18-215; I01HX002780-01; Schroeck (PI)
(~\$1,100,000 in direct funds)
“Implementing Risk-Aligned Bladder Cancer Surveillance”
The major goal of this 6-site project is to develop and pilot test a set of implementation strategies for risk-aligned bladder cancer surveillance.
Role: PI
- 2019 – 2021 NIH/NCI 1R21CA227606-01A1; Danforth (PI)
“Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research”
The major goal of this project is to develop and validate automated algorithms using natural language processing (NLP) to capture bladder cancer recurrence and progression from free-text pathology, urology, and imaging notes.
Role: Consultant
- PREVIOUS:**
- 2018-2019 Western Institute for Biomedical Research [No award number]; Lynch (PI)
(\$30,000 in direct funds)
“Gender disparities in the delay of bladder cancer diagnosis in VA”
The major goal of this project was to determine whether any gender disparities exist in the time from symptom development to bladder cancer diagnosis in VA.
Role: Consultant
- 2015-2019 Dow Career Development Award, Dept. of Surgery, Dartmouth-Hitchcock; Schroeck (PI)
Medical Center (\$300,000 in direct funds)
“Understanding Variation in Risk-Aligned Care for Early Stage Bladder Cancer”
This award provided start-up funding to understand tumor surveillance practices among Veterans with early stage bladder cancer.
Role: PI
Mentors: Philip P. Goodney, MD, MS & Todd A. MacKenzie, PhD
- 2015-2018 Conquer Cancer Foundation Career Development Award; Schroeck (PI)
(\$200,000 in direct funds)
“Understanding Risk-Aligned Care for Early-Stage Bladder Cancer”
This three year award provided funding for analytic support to characterize variation in patterns of bladder cancer care, to identify factors associated with risk-aligned care, and to examine the extent to which risk-aligned care is associated with outcomes.
Role: PI
Mentors: Philip P. Goodney, MD, MS & Todd A. MacKenzie, PhD
- 2016-2018 NIH/NCI R25CA171994; Brownson (PI)
“Mentored Training for Dissemination and Implementation Research in Cancer”
The overall goal of this training program was to develop, provide, and assess the first of its kind, Mentored Training for Dissemination and Implementation Research in Cancer

(MT-DIRC) at Washington University in St. Louis. This NIH R25 education program was focused on building capacity in Dissemination & Implementation research in cancer prevention and control. The program applied state-of-the-art training methods to build capacity in post-doctoral researchers. I participated in this program as a trainee between 2016 and 2018.

Role: Trainee

- 2015-2018 NIH/NCI R21CA182659-02; Andrew (PI)
“MicroRNA Dysregulation and Bladder Cancer Prognosis”
The overall goal of this project was to identify prognostic markers of rapidly recurrent non-muscle invasive bladder cancer in primary tumor tissue.
Role: Collaborator
- 2015-2017 Department of Veterans Affairs VISN1 Career Development Award; Schroeck (PI)
(~\$600,000 in direct funds)
“Towards Risk-Aligned Care for Veterans with Early Stage Bladder Cancer”
This two year award provided salary support for me so I can develop proficiency in observational analytic methodology for national VA data. The scientific aims were to develop and validate natural language processing algorithms to abstract pertinent information from full text bladder cancer pathology reports and to define and characterize cohorts of Veterans with early stage bladder cancer.
Role: PI
Mentors: Brenda Sirovich, MD, MS; Douglas J. Robertson, MD, MPH;
Philip P. Goodney, MD, MS, & Amar Das, MD, PhD
- 2015-2016 Norris Cotton Cancer Center Pilot Funding through an American Cancer Society Institutional Research Grant (\$30,000 in direct funds); Schroeck (PI)
“Working towards Understanding Variation in Risk-Aligned Care for Early Stage Bladder Cancer.”
This one year award provided pilot funding to establish a cohort of patients with early stage bladder cancer using national VA data.
Role: PI
Mentors: Anna N. A. Tosteson, ScD & Amar K. Das, MD, PhD
- 2012-2013 American Cancer Society Postdoctoral Fellowship PF-12-118-01-CPPB; Schroeck (PI)
(\$48,000 in direct funds)
“Impact of Technology on the Quantity and Quality of Prostate Cancer Care”
This one year project clarified the extent to which technological capacity is associated with utilization of services (such as PSA testing, prostate biopsy, active treatment) and with quality of prostate cancer care.
Role: PI
Mentors: Brent K. Hollenbeck, MD, MS & David C. Miller, MD, MPH
- 2011-2013 NIH/NIDDK T32 DK07782; Wei (PI)
“Clinical Research Training in Urology”
This training grant supported a cadre of fellows receiving post-graduate training in urological health services research and health policy.
PI: John T. Wei
Role: Trainee
Mentors: John T. Wei, MD, MS & Brent K. Hollenbeck, MD, MS
- 2001-2002 Pre-doctoral research grant from the German Research Foundation (GRK333)
“The Serine-Protease Inhibitors PAI-1 and PAI-2”

This training grant supported work related to my doctoral thesis entitled "Interaction of Plasminogen Activator Inhibitor Type 1 (PAI-1) with Vitronectin: Characterization of different PAI-1 mutants."

PI: Viktor Magdolen

Role: Trainee

Faculty Mentoring

- 2018-present Rachel A. Moses, MD, MPH
Assistant Professor of Surgery(Urology), Geisel School of Medicine
Research mentor providing guidance on refining research projects and grant applications – obtained an NIDDK R21 in 2020
- 2018 Hedwig Schroeck, MD
Assistant Professor of Anesthesiology, Geisel School of Medicine
Provided guidance in research methods, specifically related to work on a systematic review

Resident / Student Advising and Mentoring

- 2019-present Chiamaka L. Okorie, Medical Student, Geisel School of Medicine
- 2019-present Michael E. Rezaee, MD, MPH
Dartmouth Urology Resident
- 2017-2019 David S. Han, MS
Geisel School of Medicine Medical Student, graduate student at The Dartmouth Institute
Graduated with MS degree from The Dartmouth Institute in June 2018
Received a Norris Cotton Cancer Center Travel Award for his presentation at the 113th American Urological Association Annual Meeting
Won an MS Capstone Award for his project
Currently urology resident at Columbia University, New York, NY
- 2015-2017 Kevin Koo, MD, MPH, MPhil
Dartmouth Urology Resident
Graduated from Dartmouth urology residency in June 2018
Currently endourology fellow at Johns Hopkins Department of Urology
- 2015-2016 Erik A. Pattison, MD
Dartmouth Urology Resident
Graduated from Dartmouth Urology residency in June 2016
Currently staff urologist at Dartmouth Hitchcock Keene
- 2015-2016 Vernon M. Pais, Jr., MD, MS
The Dartmouth Institute graduate student (MS candidate)
Graduated with MS degree from The Dartmouth Institute in June 2018
Won an MS Capstone Award for his project
Currently Associate Professor of Urology at the Geisel School of Medicine at Dartmouth

National Service

- 2020 Member American Urological Association Quality Improvement and Patient Safety Committee
- 2019/2020 Scientific Program Chair for the Annual Meeting of the Urological Association for American Veterans (USAV)
- 2019 Moderator, Poster Session MP43: Bladder Cancer: Non-invasive III, Annual meeting of the American Urological Association, Chicago, IL
- 2017-2019 Member, Scientific Program Committee for the Annual Meeting of the Urological Association for American Veterans (USAV)

Local and Regional Service

- 2017-present Member, Geisel School of Medicine Faculty Council
 2017 Moderator, Poster Session I: Translational Research/Oncology, Annual meeting of the New England Section of the American Urological Association, Montreal, CA
 2017-2019 Member, LASER safety committee, White River Junction VA Medical Center
 2014-2018 Member, Cancer committee, White River Junction VA Medical Center

Volunteer Service

- 2015 Speaker at the American Cancer Society Northern New England Regional Staff Meeting.
 2006-2010 Screening physician in the free prostate cancer screening clinics, Lincoln Community Health Center, Durham, NC
 2007 Mentor for “Partnering Research Involving Mentoring and Education” (PRIME) in Prostate Cancer, a Department of Defense sponsored program for minority undergraduate students to provide mentored research experience.
 PI: Marva M. Price, DrPH.

Study Sections

- 2020 Invited external reviewer for University of Texas, San Antonio, Mays Cancer Center Pilot Grant Program
 2019-2020 Member, Patient-Centered Outcomes Research Institute (PCORI), Assessment of Prevention, Diagnosis, and Treatment Options (APDTO) study section
 2019 Member, Special Emphasis Panel Community and Health Services Research, National Institutes of Health, ZRG1 HDM-V (02) M
 2018 Member, Nursing and Related Clinical Sciences, National Institutes of Health, ZRG1 NRCS-V (08) (3 study sections in 2018)
 2017-2019 Member, Dartmouth Synergy translational pilot grants study section (1 study section per year)
 2017 Member, Patient-Centered Outcomes Research Institute (PCORI), Pragmatic Clinical Studies study section
 2014 Ad hoc reviewer for Prostate Cancer UK Foundation grants

Peer-Review Service

- 2020 European Urology Oncology
 2019 Nature Publishing: Scientific Reports
 2018; 2019 Journal of Clinical Oncology, Clinical Cancer Informatics
 2017 Ad hoc reviewer for VA HSR&D Annual Meeting abstracts
 2017 Healthcare: The Journal of Delivery Science and Innovation
 since 2016 Bladder Cancer (BLC)
 2016 The American Journal of the Medical Sciences
 since 2015 Cochrane Urology Group
 since 2015 European Urology Focus
 2015 BMC Research Notes
 2014 PharmacoEconomics
 since 2014 European Urology
 2013 Prostate Cancer
 2012; 2018 Journal of Oncology Practice
 since 2012 PLOS One
 since 2012 Urologic Oncology

since 2011 BJU International
 since 2011 Urology
 since 2011 Cancer
 2010 Asian Journal of Andrology
 since 2009 Journal of Urology
 2006-2018 Prostate Cancer and Prostatic Diseases

Teaching Activities

2018 Member of the Dartmouth Urology Residency Program's Program Evaluation Sub-Committee on resident rotations
 2017-present Faculty leader of the monthly urology Journal Club
 2016-2017 Member of the Dartmouth Urology Residency Program's "Self Study" Committee
 2015-2017 Directing Urology "Enrichment" Elective for 1st and 2nd year Medical Students at the White River Junction VAMC
 2015-present Member of the White River Junction VA's Residency Program Directors Committee
 2014-present Member of the Dartmouth Urology Residents' Core Competency Committee, Dartmouth Hitchcock Medical Center
 2012-2014 Proctor for Open Skills Testing in the Clinical Simulation Center University of Michigan
 2011-2013 Outcomes Associated with Radical Prostatectomy, Pre-Operative Seminar on Recovery after Prostate Cancer Surgery Department of Urology, University of Michigan, Ann Arbor, MI
 2011-2013 Urologic clinical instructor for male genitourinary exam, 2nd year medical students University of Michigan Medical School, Ann Arbor, MI

Manuscripts

1. Rezaee ME, Lynch KE, Li Z, MacKenzie TA, Seigne JD, Robertson DJ, Sirovich B, Goodney PP, **Schroeck FR**. The Impact of Low- Versus High-Intensity Surveillance Cystoscopy on Surgical Care and Cancer Outcomes in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC). **PLoS One**. 2020 Mar 23;15(3):e0230417. doi:10.1371/journal.pone.0230417. PMID: PMC7089561
2. **Schroeck FR**, St Ivany A, Lowrance W, Makarov DV, Goodney PP, Zubkoff L. Patient Perspectives on the Implementation of Risk-Aligned Bladder Cancer Surveillance: Systematic Evaluation Using the Tailored Implementation for Chronic Diseases Framework. **JCO Oncol Pract**. 2020 Mar 2; doi: 10.1200/JOP.19.00576. epub ahead of print
3. Lynch KE, Viernes B, Khader K, DuVall SL, **Schroeck FR**. Sex and the Diagnostic Pathway to Bladder Cancer among Veterans: No Evidence of Disparity. **Womens Health Issues**. 2020; 30(2):128-135. PMID: 31870696.
4. Raskolnikov D, Brown B, Holt SK, Ball AL, Lotan Y, Strobe S, **Schroeck F**, Ullman R, Lipman R, Smith AB, Gore JL. Reduction of Pain During Flexible Cystoscopy: A Systematic Review and Meta-Analysis. **J. Urol**. 2019; doi: 10.1097/JU.000000000000399. [Epub ahead of print]
5. **Schroeck FR**, Lynch KE, Li Z, MacKenzie TA, Han DS, Seigne JD, Robertson DJ, Sirovich B, Goodney PP. The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer. **Cancer**. 2019; 125(18):3147-3154. PMID: PMC6717029
6. Han DS, Lynch KE, Chang JW, Sirovich B, Robertson DJ, Swanton AR, Seigne JD, Goodney PP, **Schroeck FR**. Overuse of Cystoscopic Surveillance among Patients with Low-Risk Non-Muscle-Invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors. **Urology**. 2019; 131:112-119. PMID: PMC6711796
7. Modi PK, Herrel LA, Kaufman SR, Yan P, Borza T, Skolarus TA, **Schroeck FR**, Hollenbeck BK,

- Shahinian VB. Urologist Practice Structure and Spending for Prostate Cancer Care. **Urology** 2019; 130:65-71. PMID: PMC6660353
8. Andrew AS, Karagas MR, **Schroeck FR**, Marsit CJ, Schned AR, Pettus JR, Armstrong DA, Seigne JD. MicroRNA dysregulation and non-muscle invasive bladder cancer prognosis. **Cancer Epidemiol Biomarkers Prev.** 2019; 28(4):782-788. PMID: PMC6473178
 9. Schroeck H, Welch TL, Rovner MS, Johnson HA, **Schroeck FR**. Anesthetic challenges and outcomes for procedures in the intraoperative magnetic resonance imaging suite: A systematic review. **J Clin Anesth.** 2018; 54:89-101.
 10. **Schroeck FR**, Lynch KE, Chang Jw, MacKenzie TA, Seigne JD, Robertson DJ, Goodney PP, Sirovich B. Extent of Risk-Aligned Surveillance for Cancer Recurrence Among Patients With Early-Stage Bladder Cancer. **JAMA Network Open.** 2018;1(5):e183442. doi:10.1001/jamanetworkopen.2018.3442. PMID: PMC6241521
 11. Han DS, Zhou W, Seigne JD, Lynch KE, **Schroeck FR**. Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries. **Urology.** 2018; 22:83-88. PMID: PMC6295281
 12. Luckenbaugh AN, Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Skolarus TA, Norton EC, **Schroeck FR**, Jacobs BL, Miller DC, Hollingsworth JM, Shahinian VB, Borza T. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. **Urology.** 2018; 116:68-75. PMID: PMC5975111
 13. Welch HG, Skinner JS, **Schroeck FR**, Zhou W, Black WC. Regional Variation of Computed Tomographic Imaging in the United States and the Risk of Nephrectomy. **JAMA Intern Med.** 2018; 178(2):221-227. PMID: PMC5838611
 14. Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Borza T, **Schroeck FR**, Jacobs BL, Skolarus TA, Shahinian VB. Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly. **Eur Urol.** 2018; 73(4):491-498. PMID: PMC5817042
 15. **Schroeck FR**, Patterson OV, Alba PR, Pattison EA, Seigne JD, DuVall SL, Robertson DJ, Sirovich B, Goodney PP. Development of a Natural Language Processing Engine to Generate Bladder Cancer Pathology Data for Health Services Research. **Urology.** 2017; 110:84-91. PMID: PMC5696035
 16. **Schroeck FR**, Sirovich B, Seigne JD, Robertson DJ, Goodney PP. Assembling and validating data from multiple sources to study care for Veterans with bladder cancer. **BMC Urol.** 2017; 17(1):78. PMID: PMC5585934
 17. Koo K, Zubkoff L, Sirovich BE, Goodney PP, Robertson DJ, Seigne JD, **Schroeck FR**. The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making. **Urology.** 2017; 108: 122-128. PMID: PMC5626609
 18. **Schroeck FR**, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, Hu J. Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. **Eur Urol.** 2017; 72(5): 712-735. PMID: PMC5623181
 19. Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, **Schroeck FR**, Bekelman JE, Kahn JM, Nelson JB, Barnato AE. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer. **Cancer.** 2017; 123(15):2945-2954. PMID: PMC5517344
 20. Reinstatler L, **Schroeck FR**, Hyams ES. Ensuring Evidence-Based Practice: A Study of Factors Associated with Nonuse of American Urological Association Guidelines. **Urology Practice.** 2017; 4(1):25-29.
 21. Raffin E, Tundo G, **Schroeck F**. Pneumoscotum With Extensive Penile and Abdominal Subcutaneous Emphysema: A Case Report of Uncertain Etiology. **Urol Case Rep.** 2017; 11:50-52. PMID: PMC5279739
 22. Herrel LA, Kaufman SR, Yan P, Miller DC, **Schroeck FR**, Skolarus TA, Shahinian VB,

- Hollenbeck BK. Healthcare integration and quality among men with prostate cancer. **J Urol.** 2017; 197(1):55-60. PMID: PMC5161569
23. **Schroeck FR**, Pattison EA, Denhalter DW, Patterson OV, DuVall SL, Seigne JD, Robertson DJ, Sirovich B, Goodney PP. Early Stage Bladder Cancer - Do Pathology Reports Tell Us What We Need to Know? **Urology.** 2016; 98:58-63. PMID: PMC5116267
 24. Skolarus TA, Jacobs BL, **Schroeck FR**, et al: Understanding Readmission Intensity After Radical Cystectomy. **J. Urol.** 2015; 193: 1500-1506.
 25. **Schroeck FR**, Kaufman SR, Jacobs BL, et al: Receipt of "Best Care" According to Current Quality of Care Measures and Outcomes Among men with Prostate Cancer. **J. Urol.** 2015; 193: 500-504. PMID: PMC4305472
 26. **Schroeck FR**, Kaufman SR, Jacobs BL, et al: Technology Diffusion and Prostate Cancer Quality of Care. **Urology** 2014; 84: 1066-1072. PMID: PMC4254669
 27. Zhang Y, Hollenbeck BK, **Schroeck FR**, et al: Managed Care and the Dissemination of Robotic Prostatectomy. **Surg Innov.** 2014; 21: 566-571. PMID: PMC4733534
 28. **Schroeck FR**, Kaufman SR, Jacobs BL, et al: Adherence to Performance Measures and Outcomes among Men Treated for Prostate Cancer. **J. Urol.** 2014; 192: 743-748. PMID: PMC4143464
 29. Jacobs BL, **Schroeck FR**, Hollenbeck BK: Intensity-modulated radiation therapy for prostate cancer: Letter to the editor. **NEJM** 2014; 370: 679.
 30. Filson CP, **Schroeck FR**, Ye Z, Wei JT, Hollenbeck BK, Miller DC: Variation in use of active surveillance among men undergoing expectant management for early-stage prostate cancer. **J. Urol.** 2014; 192: 75-81.
 31. **Schroeck FR**, Kaufman SR, Jacobs BL, et al: Regional Variation in the Quality of Prostate Cancer Care. **J. Urol.** 2014; 191: 957-963. PMID: PMC3980045
 32. **Schroeck FR**, Kaufman SR, Jacobs BL, et al: The Impact of Technology Diffusion on Treatment for Prostate Cancer. **Med Care** 2013; 51: 1076-1084. PMID: PMC3916901
 33. Jacobs BL, Zhang Y, **Schroeck FR**, et al: Use of Advanced Treatment Technologies among Men at Low Risk of Dying from Prostate Cancer. **JAMA** 2013; 309: 2587-2595. PMID: PMC3857348
 34. **Schroeck FR**, Kaufman SR, Jacobs BL, et al: Technology Diffusion and Diagnostic Testing for Prostate Cancer. **J. Urol.** 2013; 190: 1715-1720. PMID: PMC3828122
 35. **Schroeck FR**, Hollingsworth JM, Hollenbeck BK, et al: Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. **Urology** 2013; 81: 1177-83.
 36. **Schroeck FR**, Skolarus TA: Editorial comment re: Factors associated with reduction in use of neoadjuvant androgen suppression therapy prior to radical prostatectomy. **Urology** 2013; 81: 751.
 37. **Schroeck FR**, Zuhlke KA, Siddiqui J, et al: Testing for the recurrent *HOXB13* G84E germline mutation in men with clinical indications for prostate biopsy. **J. Urol.** 2013; 189: 849-53.
 38. Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, **Schroeck FR**, Hollenbeck BK: Certificate of Need Legislation and the Dissemination of Robotic Surgery for Prostate Cancer. **J. Urol.** 2013; 189: 80-5.
 39. Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, **Schroeck FR**, Hollenbeck BK: Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer. **Urology** 2012; 80: 1236-42.
 40. **Schroeck FR**: Editorial Comment re: Baseline Functional Status May Predict Decisional Regret Following Robotic Prostatectomy. **J. Urol.** 2012; 188: 2218.
 41. **Schroeck FR**, Hollingsworth JM, Kaufman SR, et al: Population Based Trends in the Surgical Treatment of Benign Prostatic Hyperplasia. **J. Urol.** 2012; 188: 1837-41.
 42. Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, **Schroeck FR**, Hollenbeck BK: Certificate of Need Regulations and the Diffusion of Intensity-modulated Radiotherapy. **Urology** 2012; 80: 1015-20.

43. **Schroeck FR**, Hollingsworth JM, Kaufman SR, et al: Introduction of Laser Technology and Procedure Use for Benign Prostatic Hyperplasia: Data from Florida. **Urology** 2012; 80: 678–83.
44. Kopp RP, Stroup SP, **Schroeck FR**, et al: Are Repeat Prostate Biopsies Safe? A Cohort Analysis From the SEARCH Database. **J. Urol.** 2012; 187: 2056–2060.
45. **Schroeck FR**, Krupski TL, Stewart SB, et al: Pretreatment Expectations of Patients Undergoing Robotic Assisted Laparoscopic or Open Retropubic Radical Prostatectomy. **J. Urol.** 2012; 187: 894–898.
46. Kimura M, Bañez LL, **Schroeck FR**, et al: Factors Predicting Early and Late Phase Decline of Sexual Health-Related Quality of Life Following Radical Prostatectomy. **J Sex Med** 2011; 8: 2935–43.
47. Hammerich KH, **Schroeck FR**, West D, et al: Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist. **Oncology (Williston Park, N.Y.)** 2010; 24: 757–760.
48. **Schroeck FR**, Kattan MW, Moul JW, et al: Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. **BJU Int** 2010; 105: 1654–1659.
49. Jayachandran J, **Schroeck FR**, Sun L, et al: The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database. **BJU Int** 2010; 105: 180–184.
50. Chino J, **Schroeck FR**, Sun L, et al: Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. **BJU Int** 2009; 104: 1496–1500.
51. Stackhouse DA, Sun L, **Schroeck FR**, et al: Factors predicting prostatic biopsy Gleason sum under grading. **J. Urol.** 2009; 182: 118–122; discussion 123–124.
52. Polascik TJ, Mayes JM, **Schroeck FR**, et al: Patient selection for hemiablativ focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. **Cancer** 2009; 115: 2104–2110.
53. **Schroeck FR**, Aronson WJ, Presti JC Jr, et al: Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? **BJU Int** 2009; 103: 603–608.
54. **Schroeck FR**, Donatucci CF, Smathers EC, et al: Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. **Cancer** 2008; 113: 2687–2694.
55. **Schroeck FR**, Krupski TL, Sun L, et al: Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. **Eur. Urol.** 2008; 54: 785–793.
56. **Schroeck FR**, Sun L, Freedland SJ, et al: Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. **BJU Int** 2008; 102: 28–32.
57. **Schroeck FR**, De Sousa CAP, Kalman RA, et al: Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate. **Urology** 2008; 71: 597–601.
58. **Schroeck FR**, Sun L, Freedland SJ, et al: Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. **Prostate Cancer Prostatic Dis** 2008; 11: 371–376.
59. Magdolen U, **Schroeck F**, Creutzburg S, et al: Non-muscle alpha-actinin-4 interacts with plasminogen activator inhibitor type-1 (PAI-1). **Biol. Chem** 2004; 385: 801–808.
60. **Schroeck F**, Arroyo de Prada N, Sperl S, et al: Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn. **Biol. Chem** 2002; 383: 1143–1149.
61. Arroyo De Prada N, **Schroeck F**, Sinner E-K, et al: Interaction of plasminogen activator

- inhibitor type-1 (PAI-1) with vitronectin. **Eur. J. Biochem** 2002; 269: 184–192.
62. Magdolen V, Bürgle M, De Prada NA, Schmiedeberg N., Riemer C., **Schroeck F**, et al: Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). **Biol. Chem** 2001; 382: 1197–1205.

Review Articles and Editorials

1. **Schroeck FR**: Editorial Comment on: Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer within a Large, Diverse, Integrated Delivery System. **Urology** 2019; 131:102.
2. Welch HG, **Schroeck FR**. Uncoupling Diagnosis and Treatment of Incidentally Imaged Renal Masses. *JAMA Intern Med.* 2018;178(5):729.
3. Koczwara B, Stover AM, Davies L, Davis MM, Fleisher L, Ramanadhan S, **Schroeck FR**, Zullig LL, Chambers DA, Proctor E. Harnessing the Synergy Between Improvement Science and Implementation Science in Cancer: A Call to Action. **J Oncol Pract.** 2018 Jun;14(6):335-340. PMID: PMC6075851
4. **Schroeck FR**, Smith N, Shelton JB. Implementing risk-aligned bladder cancer surveillance care. **Urol Oncol.** 2018 May;36(5):257-264.
5. **Schroeck FR**, Sirovich BE: Editorial Comment on: Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. **Urology** 2015; 86: 1198-1199.
6. **Schroeck FR**, Wei JT: Reply by authors re: Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. **Urology** 2013; 82: 981.
7. **Schroeck FR**, Jacobs BL, Hollenbeck BK: Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. **ASCO Educational Book** 2013; 2013: 278-83.
8. **Schroeck FR**, Montie JE, Hollenbeck BK: Surveillance Strategies for Non-Muscle Invasive Bladder Cancer, **AUA update series**; Lesson 32, 2012.
9. Moul JW, Mouraviev V, Sun L, **Schroeck FR**, Polascik TJ: Prostate cancer: the new landscape. **Curr Opin Urol** 2009; 19: 154–160.

Book Chapters

1. **Schroeck FR**, Wei JT: Expanded Prostate Cancer Index Composite (EPIC). In Michalos A (ed): *Encyclopedia of Quality of Life Research*, ed. Michalos A., Springer, 2013
2. **Schroeck FR.**, Moul JW: Adenomatoid tumors. In Gomella LG (ed): *The 5-Minute Urology Consult 2nd edition*, Lippincott Williams & Wilkins, 2009
3. **Schroeck FR.**, Moul JW: Medullary cystic kidney disease. In Gomella LG (ed): *The 5-Minute Urology Consult 2nd edition*, Lippincott Williams & Wilkins, 2009
4. **Schroeck FR.**, Moul JW: Umbilical abnormality (drainage and masses). In Gomella LG (ed): *The 5-Minute Urology Consult 2nd edition*, Lippincott Williams & Wilkins, 2009

Presentations

Invited Presentations

- Department of Urology, Vanderbilt University, Grand Rounds: “Using National VA Data to Improve Care for Patients with Early Stage Bladder Cancer”, November 25th, 2019, Nashville, TN
- Department of Urology, Emory University, Grand Rounds: “Using National VA Data to Improve Care for Patients with Early Stage Bladder Cancer”, November 21st, 2019, Atlanta, GA
- Division of Urology, University of Maryland Medical Center, Grand Rounds: “Using National VA Data to Improve Care for Patients with Early Stage Bladder Cancer”, October 17th, 2019, Baltimore, MD
- Department of Urology, Indiana University School of Medicine, Grand Rounds: “Using National VA Data to Improve Care for Patients with Early Stage Bladder Cancer”, October 16th, 2019,

Indianapolis, IN

Informatics, Decision-Enhancement and Analytic Sciences Center (IDEAS 2.0), VA HSR&D Center of Innovation (COIN), Salt Lake City: "Using National VA Data to Improve Care for Veterans with Early Stage Bladder Cancer", September 20th, 2019, Salt Lake City, UT

American College of Surgeons Clinical Congress, Panel Session 324 "Implementation Science: The Avenue Forward in Health Services Research": "Using implementation science to improve risk-aligned cancer care", October 24th, 2018, Boston, MA

Washington University St. Louis, Dept. of Urology Grand Rounds, "Using data and implementation science to improve bladder cancer care within VA", June 9th, 2017, St. Louis, MO

Department of Surgery Grand Rounds, Dartmouth Hitchcock Medical Center, "Leveraging Full Text Pathology Data to Improve Bladder Cancer Care", July 1st, 2016, Lebanon, NH

Washington University St. Louis, Dept. of Urology Grand Rounds, "Leveraging "Big Data" to Advance Bladder Cancer Care", June 10th, 2016, St. Louis, MO

Technische Universität München, Dept. of Urology Grand Rounds, "Leveraging "Big Data" to Advance Bladder Cancer Care", April 28th, 2016, Munich, Germany

Department of Pathology Grand Rounds, Dartmouth Hitchcock Medical Center, "Leveraging Full Text Pathology Data to Improve Bladder Cancer Care", March 22nd, 2016, Lebanon, NH

Norris Cotton Cancer Center Grand Rounds, Dartmouth Hitchcock Medical Center, "Towards risk-aligned care for patients with early stage bladder cancer", October 27th, 2015, Lebanon, NH

Northeastern Genitourinary Oncology Symposium, "The Impact of Technology on the Quantity and Quality of Prostate Cancer Care", May 2nd, 2015, Burlington, VT

28th Reed M. Nesbit Urologic Society Meeting, "The Impact of Technology on Prostate Cancer Quality of Care", October 18th, 2013, Ann Arbor, MI

Grand Rounds Emory University, "The Impact of Technology Diffusion on the Quantity and Quality of Prostate Cancer Care", September 26th, 2013, Atlanta, GA

Grand Rounds University of Rochester, "The Impact of Technology Diffusion on the Quantity and Quality of Prostate Cancer Care", August 21st, 2013, Rochester, NY

HSR fellow seminar in conjunction with the Ann Arbor Health Services Research Symposium, "The Impact of Technology on Prostate Cancer Care", September 5th, 2012, Ann Arbor, MI

Sanofi-Aventis Prostate Practicum, "Evidence Based Research on Open vs. Robotic Approaches", September 9-11, 2008 and May 19-20, 2009, Durham, NC

Abstract Presentations

American Urological Association, 2020 – Online Meeting due to COVID-19

Rezaee ME, Lynch KE, Li Z, MacKenzie TA, Seigne JD, Robertson DJ, Sirovich B, Goodney PP, **Schroeck FR**. The Impact of Low- Versus High-Intensity Surveillance Cystoscopy on Surgical Care and Cancer Outcomes in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).

– Selected for Presentation in the Virtual Press Program

Schroeck FR, St Ivany A, Lowrance W, Makarov DV, Goodney PP, Zubkoff L. Patient Perspectives on the Implementation of Risk-Aligned Cystoscopic Surveillance for Non-Muscle Invasive Bladder Cancer: Systematic Evaluation Using the Tailored Implementation for Chronic Diseases Framework.

13th Annual Conference on the Science of Dissemination and Implementation in Health, Arlington, VA, 2019.

Schroeck FR, St Ivany A, Lowrance W, Makarov DV, Goodney PP, Zubkoff L. Patient perspectives on the implementation of risk-aligned surveillance for non-muscle invasive bladder cancer – mixed-methods evaluation using the tailored implementation for chronic diseases (TICD) framework.

New England Section of the American Urological Association, Providence, RI, 2019

Schroeck FR, Lynch KE, Li Z, Li Z, MacKenzie TA, Han D, Seigne JD, Robertson DJ, Sirovich B, Goodney PP. The Impact of Frequent Cystoscopy on Surgical Care and Cancer Outcomes among Patients with Low-Risk Non-Muscle-Invasive Bladder Cancer

Rezaee ME, Lynch KE, Li Z, Li Z, MacKenzie TA, Seigne JD, Robertson DJ, Sirovich B, Goodney PP, **Schroeck FR**. The Impact of Low- Versus High-Intensity Surveillance Cystoscopy on Surgical Care and Cancer Outcomes in Patients with High- Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

American Urological Association, Chicago, 2019

Schroeck FR, Lynch KE, Li Z, MacKenzie TA, Seigne JD, Han D, Robertson DJ, Sirovich B, Goodney PP. Risks and Benefits of Frequent Surveillance Cystoscopy among Patients with Low-risk Non-Muscle Invasive Bladder Cancer (NMIBC).

New England Section of the American Urological Association, Hartford, CT, 2018

Schroeck FR, Lynch KE, Chang JW, MacKenzie TA, Seigne JD, Robertson DJ, Goodney PP, Sirovich B. A National Study of Risk-aligned Bladder Cancer Surveillance - Recommended but Rarely Practiced.

Han DS, Swanton AR, Lynch KE, Chang JW, Sirovich B, Robertson DJ, Seigne JD, Goodney PP,

Schroeck FR. Overuse of Cystoscopic Surveillance Among Patients with Low-risk Non-muscle-Invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Characteristics.

American Urological Association, San Francisco, 2018

Schroeck FR, Lynch KE, Chang JW, Robertson DJ, Seigne JD, Goodney PP, Sirovich B. A national study of risk-aligned surveillance practice for non-muscle invasive bladder cancer.

Han DS, Swanton A, Lynch KE, Chang JW, Sirovich B, Robertson DJ, Seigne JD, Goodney PP,

Schroeck FR. Overuse of cystoscopic surveillance among patients with non-muscle invasive bladder cancer – a national study of patient, provider, and facility factors.

American Medical Informatics Association (AMIA), Washington DC, 2017

Alba PR, DuVall SL, Workman TE, **Schroeck FR**, Patterson OV. Pathology Information Extraction in Bladder Cancer Surveillance.

New England Section of the American Urological Association, Montreal, CA, 2017

Schroeck FR, Sirovich B, Seigne JD, Robertson DJ, Goodney PP. Leveraging Big Data to Study Bladder Cancer Care.

Schroeck FR, Patterson OV, Alba P, DuVall SL, Sirovich B, Robertson DJ, Seigne JD, Goodney PP. Harnessing Full Text Pathology Data from the Electronic Health Record to Advance Bladder Cancer Care - Development of a Natural Language Processing System to Generate Longitudinal Pathology Data.

Department of Veterans Affairs HSR&D National Conference, Washington DC, 2017

Schroeck FR, Patterson OV, Alba PR, DuVall SL, Sirovich B, Robertson DJ, Seigne JD, Goodney PP. Development of a Natural Language Processing Engine to Generate Pathology Data to Advance Bladder Cancer Care.

American Urological Association, Boston, 2017

Schroeck FR, Patterson O, Alba P, et al.: Harnessing full text pathology data from the electronic health record to advance bladder cancer care – Development of a Natural Language Processing system to generate longitudinal pathology data.

Koo K, Zubkoff L, Sirovich B, Seigne JD, Goodney PP, **Schroeck FR**: The Burden of Cystoscopic

Bladder Cancer Surveillance—Anxiety, Discomfort, and Patient Preferences for Decision Making
Schroeck FR, Sirovich B, Seigne JD, Robertson DJ, Goodney PP. Leveraging Big Data to Study Bladder Cancer Care.

17th Annual Meeting of the Society of Urologic Oncology, San Antonio, 2016

Koo K, Zubkoff L, Sirovich BE, Seigne JD, Goodney PP, **Schroeck FR**: The Burden of Cystoscopic Bladder Cancer Surveillance - Anxiety, Discomfort, and Patient Preferences for Decision Making

American Urological Association, San Diego, 2016

Schroeck FR, Pattison EA, Denhalter D, et al.: Surveillance for Bladder Cancer Patients – Do Pathology Reports Tell Us What We Need to Know?

Pattison EA, Denhalter D, Patterson O, DuVall S, Seigne J, Sirovich B, Goodney P, Robertson D, **Schroeck FR**. Leveraging Bladder Cancer Pathology Reports for Research: Gleaning Meaning Despite Widely Variable Language.

American Urological Association, Orlando, 2014

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Suskind AM, Hollenbeck BK: Do Prostate Cancer Patients Receiving the “Best Care” have Better Outcomes?

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Suskind AM, Hollenbeck BK: Healthcare System Quality and Outcomes among Men Treated for Prostate Cancer

Suskind AM, Clemens JQ, Zhang Y, **Schroeck FR**, Hollenbeck BK: Physician use of sacral neuromodulation in Medicare beneficiaries; Are physicians who are high testers also high implanters?

14th Annual SUO Winter Meeting, Young Urologic Oncologist Program, Bethesda, 2013

Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strobe SA, Hollenbeck BK: The Impact of Technology Diffusion on Treatment of Prostate Cancer

North Central Section of the American Urological Association, Naples, FL, 2013

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Hollingsworth JM, Miller DC, Suskind AM, Hollenbeck BK: The Quality of Prostate Cancer Care in the United States.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Suskind AM, Hollenbeck BK: The Impact of Technology Diffusion on Treatment of Prostate Cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Suskind AM, Hollenbeck BK: Technology Diffusion and Diagnostic Testing for Prostate Cancer.

Suskind AM, Clemens JQ, Dunn RL, Zhang Y, Stoffel JT, **Schroeck FR**, Jacobs BL, Hollenbeck BK: Quality of outpatient sling surgery for urinary incontinence in Medicare beneficiaries.

Academy Health Annual Meeting, Baltimore, 2013

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Hollingsworth JM, Miller DC, Suskind AM, Hollenbeck BK: Regional Variation in the Quality of Prostate Cancer Care.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Suskind AM, Hollenbeck BK: Technology Diffusion and Diagnostic Testing for Prostate Cancer.

Suskind AM, Dunn RL, Zhang Y, Hollingsworth JM, Jacobs BL, **Schroeck FR**, Hollenbeck BK: Assessing the intended effects of ambulatory surgery centers on the delivery of outpatient procedures.

ASCO Annual Meeting, Chicago, 2013

Schroeck FR, Kaufman SR, Jacobs BL, Miller DC, Hollenbeck BK: The Impact of Technology Diffusion on Treatment for Prostate Cancer.

American Urological Association, San Diego, 2013

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Hollingsworth JM, Miller DC, Suskind AM, Hollenbeck BK: Regional Variation in the Quality of Prostate Cancer Care.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Suskind AM, Hollenbeck BK: Technology and Prostate Cancer Quality of Care.

Jacobs BL, Zhang Y, **Schroeck FR**, Skolarus TA, Suskind AM, Weizer AZ, Montgomery JS, Wei JT, Montie JE, Hollingsworth JM, Miller DC, Hollenbeck BK: The dissemination of intensity-modulated radiotherapy and robotic prostatectomy among men at low risk of dying from prostate cancer.

Suskind AM, Dunn RL, Yun Z, Hollingsworth JM, Jacobs BL, **Schroeck FR**, Hollenbeck BK: Assessing the intended effects of ambulatory surgery centers on the delivery of outpatient urologic procedures.

Suskind AM, Clemens JQ, Dunn RL, Hollingsworth JM, Yun Z, Jacobs BL, **Schroeck FR**, Hollenbeck BK: Comparative effectiveness of sling surgery in Medicare beneficiaries.

13th Annual SUO Winter Meeting, Young Urologic Oncologist Program, Bethesda, 2012

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Hollingsworth JM, Miller DC, Hollenbeck BK: Large regional variation in quality of prostate cancer care highlights opportunity for quality improvement.

American Urological Association, Atlanta, 2012

Schroeck FR, Hollingsworth JM, Kaufman SR, Dunn RL, Hollenbeck BK, Wei JT: Population based trends in the surgical treatment of benign prostatic hyperplasia.

Schroeck FR, Hollingsworth JM, Kaufman SR, Dunn RL, Hollenbeck BK, Wei JT: Adoption of laser technology is associated with increased BPH surgery rates.

Schroeck FR, Hollingsworth JM, Kaufman SR, Dunn RL, Hollenbeck BK, Wei JT: Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia.

Southeastern Section of the American Urological Association, New Orleans, 2011

Schroeck FR, Wiener JS: T. Leon Howard Imaging Session: Case #1: A 16 y/o male with right inguinal and scrotal pain.

10th Annual SUO Winter Meeting, Bethesda, 2009

Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti JC, Terris MK, et al.: Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.

American Urological Association, Chicago, 2009

Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti JC, Jr, Terris MK, et al.: Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.

Schroeck FR, Aronson WJ, Presti JC, Jr, Terris MK, Kane CJ, Amling CL, et al.: Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?

Jayachandran J, **Schroeck FR**, Sun L, Gerber L, Moreira DM, Moul JW, et al.: The SEARCH nomogram for risk stratification in intermediate risk group of men with prostate cancer: Validation in the Duke Prostate Center database.

Southeastern Section of the American Urological Association, Mobile, 2009

Montague Boyd Essay Contest: **Schroeck FR**, Donatucci CF, Smathers EC, Sun L, Albala DM, Polascik TJ, et al.: Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite.

Sexual Medicine Society of North America Fall Meeting, Toronto, 2008

Schroeck FR, Donatucci CF, Smathers EC, Sun L, Albala DM, Polascik TJ, et al.: Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite.

SIU World Uro-Oncology Update, Santiago, Chile, 2008

Robertson CN, Albala DM, Sun L, **Schroeck FR**, Donatucci CF, Smith J, et al.: Stratification of Age and Gleason Grade as a Model for Selection of Optimal Candidates for Definitive Therapy of Localized Prostate Cancer.

Albala DM, Moul JW, Zorn KC, Robertson CN, **Schroeck FR**, Shikanov SA, et al.: Racial Disparity Remains Associative with Advanced Prostate Cancer in late PSA-era: An Analysis of 2784 Radical Prostatectomies After 2000.

American Urological Association, Orlando, 2008

Schroeck FR, de Sousa CAP, Kalman RA, Kalia MS, Pierre SA, Haleblan GE, et al.: "Don't let them touch me?" Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss and positive surgical margin rate.

Schroeck FR, Sun L, Levy DE, Bryan KA, Freedland SJ, Jayachandran J, et al.: Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.

Schroeck FR, Krupski TL, Sun L, Albala DM, Robertson CN, Polascik TJ, et al.: Independent predictors for dissatisfaction with and regret of treatment choice after radical prostatectomy.

3rd Annual World Robotic Urology Symposium, Orlando, 2008

Schroeck FR, Sun L, Freedland SJ, Albala DM, Mouraviev V, Polascik TJ, Moul JW: Comparison of PSA recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic prostatectomy or robot-assisted laparoscopic radical prostatectomy.

Schroeck FR, de Sousa CAP, Kalman RA, Kalia MS, Pierre SA, Haleblan GE, et al.: "Don't let them touch me?" Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss and positive surgical margin rate.

Duke Comprehensive Cancer Center Annual Meeting, 2008

Schroeck FR, Sun L, Donatucci CF, Smith J, Moul JW, Robertson CN: Stratification of age and Gleason grade as a model for selection of optimal candidates for high intensity focused ultrasound therapy of prostate cancer.

Schroeck FR, Krupski TL, Sun L, Albala DM, Robertson CN, Polascik TJ, et al.: Predictors for satisfaction and regret after three different types of radical prostatectomy

Southeastern Section of the American Urological Association, San Diego, 2008

Bryan KA, **Schroeck FR**, Williams R, Price M, Sun L, Moul JW: Independent predictors for PSA recurrence after radical prostatectomy: Gleason score 3+4 versus 4+3 and percent tumor involvement.

Schroeck FR, de Sousa CAP, Kalman RA, Kalia MS, Pierre SA, Haleblan GE, et al.: "Don't let them touch me?" Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss and positive surgical margin rate.

Mayes J, Mouraviev V, Krupski TL, Levy DE, **Schroeck FR**, Polascik TJ: Psychological aspects of altered male physiologic function after surgical treatment of prostate cancer: mean 2 year follow up.

1st Int. Workshop on Focal Therapy and Imaging of Prostate Cancer, Durham, NC, 2008

Polascik TJ, Mayes JM, **Schroeck FR**, Sun L, Madden JF, Moul JW, Mouraviev V: Patient selection for focal therapy.

American Society of Clinical Oncology - 2008 Genitourinary Cancer Symposium, San Francisco, 2008

Schroeck FR, Sun L, Freedland SJ, Albala DM, Mouraviev V, Polascik TJ, Moul JW: Comparison of PSA recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic prostatectomy or robot-assisted laparoscopic radical prostatectomy.

8th Annual SUO Winter Meeting, Bethesda, 2007

Schroeck FR, Bryan KA, Williams R, Price M, Sun L, Moul JW: Independent predictors for PSA recurrence after radical prostatectomy: Gleason score 3+4 versus 4+3 and percent tumor involvement

16th International Congress of the International Society for Fibrinolysis and Proteolysis (ISFP), Munich, Germany, 2002

Schroeck F, Sinner EK, Schmitt M, Magdolen V: Differential binding of wt-PAI-1 and the PAI-1 mutant Q123K to native and multimeric vitronectin.

2nd General Meeting of the International Proteolysis Society (IPS) associated with the International Conference on Protease Inhibitors (ICPI), Freising near Munich, Germany, 2001

Schroeck F, Arroyo de Prada N, Muehlenweg B, Wilhelm OG, Schmitt M, Magdolen V: Interaction of PAI-1 with vitronectin: characterization of different PAI-1 mutants.